感染性休克患者既往血管紧张素II受体阻滞剂暴露与个体化平均动脉压目标:SEPSISPAM试验的事后分析
该研究为SEPSISPAM试验的事后分析,纳入297例合并慢性高血压的感染性休克患者,旨在探讨既往降压药物类别与平均动脉压目标对严重急性肾损伤(KDIGO 2级或以上)的交互作用。结果显示,严重急性肾损伤共发生184例,总体与既往降压药物暴露无关;但在高平均动脉压目标组中,既往暴露于血管紧张素II受体阻滞剂(ARB)的患者严重急性肾损伤发生显著减少(校正OR 0.24,95%CI 0.09-0.66,P=0.006)。校正既往降压药物后,与生存无显著关联。提示合并慢性高血压且既往使用ARB的感染性休克患者可能从高平均动脉压目标中获益,以减少急性肾损伤风险。
要点
- 在合并慢性高血压的感染性休克患者中,高平均动脉压目标组内既往ARB暴露者严重急性肾损伤(KDIGO 2级或以上)风险显著降低(校正OR 0.24,95%CI 0.09-0.66,P=0.006)。
- 严重急性肾损伤总体发生184例,是否发生与既往任何降压药物暴露无关。
- 校正既往降压药物暴露后,平均动脉压目标与28天或90天死亡率无显著关联。
- 该分析为SEPSISPAM试验的事后分析,样本量297例,结果需前瞻性验证,不能直接作为床旁决策阈值。
适用人群与场景
- SEPSISPAM试验中合并慢性高血压且住院报告中有降压药物数据的感染性休克患者,共297例。
诊断标准与关键阈值
- 严重急性肾损伤定义为ICU期间发生KDIGO分期2级或以上。
- 高平均动脉压目标与低平均动脉压目标的具体数值原文未在摘要中提及。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:SEPSISPAM试验的事后分析;样本量297例;人群为合并慢性高血压的感染性休克患者。
- 干预与对照:比较不同平均动脉压目标(高目标 vs 低目标),并根据既往降压药物类别分层。
- 主要终点:严重急性肾损伤(KDIGO 2级或以上)发生184例,总体与既往降压药物暴露无差异。
- 关键结果:高平均动脉压目标组中,既往ARB暴露者严重急性肾损伤显著减少(校正OR 0.24,95%CI 0.09-0.66,P=0.006)。
- 次要终点:校正既往降压药物暴露后,28天和90天死亡率与平均动脉压目标无显著关联。
证据类型、等级与局限
- 证据类型:RCT(SEPSISPAM试验)的事后分析。
- 局限:事后分析、样本量有限(297例),结果需前瞻性验证;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 对于合并慢性高血压且既往使用ARB的感染性休克患者,可考虑采用高平均动脉压目标以减少严重急性肾损伤风险,但该策略基于事后分析,需个体化评估并前瞻性验证。
- 不适用人群:原文未明确排除人群,但非慢性高血压或未使用ARB的患者不能直接外推。
- 常见陷阱:不能将校正OR 0.24视为决策阈值;平均动脉压目标的具体数值需参考SEPSISPAM试验方案。
指南或共识出处
- SEPSISPAM试验(Sepsis and Mean Arterial Pressure trial)的事后分析,发表于Crit Care Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Individualizing a target mean arterial pressure is challenging during the initial resuscitation of patients with septic shock. The Sepsis and Mean Arterial Pressure (SEPSISPAM) trial suggested that targeting high mean arterial pressure might reduce the occurrence of acute kidney injury among those included patients with a past history of chronic hypertension. We investigated whether the class of antihypertensive medications used before the ICU stay in chronic hypertensive patients was associated with the severity of acute kidney injury occurring after inclusion, according to mean arterial pressure target.
DESIGN: Post hoc analysis of the SEPSISPAM trial.
SETTING: The primary outcome was the occurrence of severe acute kidney injury during the ICU stay defined as kidney disease improving global outcome stage 2 or higher. Secondary outcomes were mortality at day 28 and mortality at day 90.
PATIENTS: All patients with chronic hypertension included in SEPSISPAM with available antihypertensive medications data in the hospitalization report were included.
MEASUREMENTS AND MAIN RESULTS: We analyzed 297 patients. Severe acute kidney injury occurred in 184 patients, without difference according to pre-ICU exposure to antihypertensive medications. Patients with pre-ICU exposure to angiotensin II receptor blockers had significantly less severe acute kidney injury in the high mean arterial pressure target group (adjusted odd ratio 0.24 with 95% CI [0.09-0.66]; p = 0.006). No statistically significant association was found after adjustment for pre-ICU exposure to antihypertensive medications and survival.
CONCLUSIONS: Our results suggest that patients with septic shock and chronic hypertension treated with angiotensin II receptor blocker may benefit from a high mean arterial pressure target to reduce the risk of acute kidney injury occurrence.
参考来源
- Demiselle J, Seegers V, Lemerle M, et al. Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial. Crit Care Med. 2021. PMID: 33591012. doi:10.1097/CCM.0000000000004872
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。